[Ip-health] Op-ed by D. Ravi Kanth in Livemint: India should not give way on IPR

Thiru Balasubramaniam thiru at keionline.org
Tue May 12 00:38:15 PDT 2015


HOME <http://www.livemint.com/>»  OPINION <http://www.livemint.com/opinion>
India should not give way on IPR
The Indian industrial and economic policy elite must not succumb to
pressures from Washington and Brussels

D. Ravi Kanth <http://www.livemint.com/Search/Link/Author/D.%20Ravi%20Kanth>

A leading Republican lawmaker in the US is upset that India is accorded a
kids glove approach on intellectual property rights (IPR). “Once again, the
(Barack Obama) administration has missed the mark,” complained congressman
Orrin Hatch, chairman of the powerful House Finance Committee. “After
squandering the opportunity to crack down on India’s rampant IP violations
in their out-of-cycle review last year, they have now issued a report that
fails to fully recognize the seriousness of India’s harmful IP policies,”
Hatch charged.
Launched 26 years ago as a unilateral crowbar mechanism to punish countries
for alleged IPR violations, the Special 301 report reviews annually the
state of enforcement of IPR protection. The US Trade Representative (USTR)
is expecting to see “substantive and measureable improvements” in India’s
IPR regime, according to deputy USTR Robert Holleyman.
Perhaps Hatch is unaware of Prime Minister Narendra Modi
<http://www.livemint.com/Search/Link/Keyword/Narendra%20Modi>’s statement
that India is ready to work “on IPR guidelines matching global standards”.
Modi did not elaborate on the global standards that he alluded to, but
there are no standards other than those in the Trade-related Aspects of
Intellectual Property Rights (TRIPS) agreement implemented by 161 countries
at the World Trade Organization. If India possessed expertise in genetic
sciences and plastic surgery in the ancient times, as Modi said last year,
it is somewhat puzzling why India should now follow “global standards” set
by one superpower or the other.
Nonetheless, the USTR reportedly acknowledged Prime Minister Modi’s April
2015 statements recommending that India align its patent laws with
international standards. The USTR’s decision to go slow on its
patent-related travails with India may seem like a small victory for the
few newly imported mandarins of the government. They are bound to claim
credit for their influence-peddling in Washington. Otherwise, the USTR
would not have turned a deaf ear to the demands for an out-of-cycle review
of India. It was not long ago that these mandarins had advised the US
lawmakers to launch a dispute against India at the WTO on the amended
Indian patent law.
The *2015 Special 301 Report* has raised several concerns against New
Delhi’s patent regime. To start with, Washington says that Section 3(d) of
India’s Patent Act “may have the effect of limiting the patentability of
potentially beneficial innovations”. This provision prevents companies from
continually extending their 20-year drug patents by tweaking with minor
changes or improvements, an “evergreening” process in the IPR jargon. It
led to the cancellation of the patent for Novartis AG’s cancer drug Glivec,
which the Supreme Court upheld.
Second, India’s application of compulsory licensing law needs “clarity” as
it affects US stakeholders such as Pfizer Inc., Merck and Co. Inc., Eli
Lilly and Co., and Abbott Laboratories, among others.
Third, India is wrongly identifying “patents as obstacles to the
dissemination of climate change technologies that would potentially
undermine incentives for innovation”.
Fourth, the enforcement of patent rights in India is cumbersome as
evidenced in Merck vs Glenmark and Cipla vs Roche.
And fifth, India lacks “an effective system for protecting against unfair
commercial use, as well as the unauthorized disclosure, of undisclosed
tests or other data generated to obtain marketing approval for
pharmaceutical and agricultural chemical products”, a unilateral demand
that Indian generic companies must generate their own data on drugs that
are out of patent.
If the US is so unduly concerned about India’s patent laws, it can simply
take New Delhi to task at the WTO. Only a fortnight ago, the US had
completed the second round of dispute settlement hearings against India on
the domestic local content requirements under the Jawaharlal Nehru National
Solar Mission for solar cells and solar modules.
In the past, Washington launched five disputes against India, beginning
with the dispute on the non-establishment of a mailbox system and exclusive
marketing rights for pharmaceutical and agricultural chemical products in
1996. The WTO’s highest court—the appellate body—ruled against India for
failing to comply with the TRIPS provisions. Consequently, New Delhi was
forced to pass legislation in early 1999 creating a mailbox for patent
But now, the US sees a danger in challenging India at the WTO on 3(d) and
other aspects of the Indian patents Act. Perhaps, it may have seen the
documentary *Fire in the Blood* released two years ago that revealed the
international solidarity behind the Indian generic industry for its yeoman
US pharmaceutical firms thrive on monopoly prices, says Nobel Prize-winning
economist Joseph Stiglitz. At a time when there are few new patents in the
pipeline and the existing patents are about to expire, Indian generic
companies pose a problem because they provide medicines at affordable
prices. “Monopolies arising from patent protection,” said Stiglitz, “are
economically inefficient in the same way that any other monopoly is, they
lead to higher prices than would be seen in a competitive market.” Further,
“if patent rights are too strong and maintained for too long, they prevent
access to knowledge, the most important input into the innovation process”,
Stiglitz argued in an interview published last month.
Asked about the optimal approach to intellectual property for a country
like India with a limited public health budget and rising disease burden,
Stiglitz said: “India has already increased patent production on medicines
relative to a few decades ago by acceding to the TRIPS agreement. Greater
intellectual property protection for medicines would, we fear, limit access
to life-saving drugs and seriously undermine the very capable indigenous
generics industry that has been critical for people’s well-being in India
and other developing countries.”
The Indian industrial and economic policy elite, particularly Prime
Minister Modi, must consider Stiglitz’s advice seriously and not succumb to
pressures from Washington and Brussels on data exclusivity and other
changes in the IPR regime through the back door. Otherwise, the Indian poor
and middle classes will hold the “Make in India” government responsible for
multinational companies jeopardizing their health and livelihood conditions!

More information about the Ip-health mailing list